Payment overview · 2025
General Payments
2 reported records · 1 companies
Healthcare provider profile · identity verified
Allopathic & Osteopathic Physicians|Internal Medicine · ARCADIA, CA · NPI 1306868617
Verified facts
CMS Open Payments records show Andrew Lee, M.D. received $183.17 in general payments during 2025 across 2 reported records.
ABIOMED accounted for 100.0% of that reported general-payment amount.
These records do not establish that a payment influenced prescribing or medical care.
Payment overview · 2025
2 reported records · 1 companies
Separate record types
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABIOMED | Unresolved — no canonical attribution shown | $183.17 | 100.0% | 2 | 2025 |
What were the payments for?
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $183.17 | 2 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Payment records were found, but the reported records did not identify a specific associated product for this analysis.
There is no explicit payment-product set available for a Part D comparison.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
None of this doctor’s payer companies has same-entity product evidence that passes the publication threshold. The site does not infer company ownership, affiliates, or generic manufacturers.
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 202 | 49 |
| Amlodipine Besylate | Amlodipine Besylate | 192 | 51 |
| Levothyroxine Sodium | Levothyroxine Sodium | 182 | 42 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 176 | 49 |
| Metformin Hcl | Metformin Hcl | 114 | 31 |
| Tamsulosin Hcl | Tamsulosin Hcl | 98 | 26 |
| Pantoprazole Sodium | Pantoprazole Sodium | 92 | 28 |
| Allopurinol | Allopurinol | 87 | 19 |
| Azithromycin | Azithromycin | 86 | 67 |
| Carvedilol | Carvedilol | 82 | 17 |
| Montelukast Sodium | Montelukast Sodium | 82 | 18 |
| Metoprolol Succinate | Metoprolol Succinate | 80 | 22 |
| Lisinopril | Lisinopril | 69 | 16 |
| Losartan Potassium | Losartan Potassium | 68 | 17 |
| Escitalopram Oxalate | Escitalopram Oxalate | 67 | 15 |
| Simvastatin | Simvastatin | 64 | 18 |
| Clopidogrel | Clopidogrel Bisulfate | 62 | 15 |
| Hydrochlorothiazide | Hydrochlorothiazide | 62 | 15 |
| Gabapentin | Gabapentin | 59 | 18 |
| Alprazolam | Alprazolam | 56 | 20 |
| Irbesartan | Irbesartan | 52 | 15 |
| Benazepril Hcl | Benazepril Hcl | 51 | 13 |
| Meloxicam | Meloxicam | 50 | suppressed |
| Xarelto | Rivaroxaban | 48 | suppressed |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 47 | 14 |
| Trazodone Hcl | Trazodone Hcl | 47 | 14 |
| Lorazepam | Lorazepam | 43 | 13 |
| Famotidine | Famotidine | 41 | 12 |
| Eliquis | Apixaban | 40 | suppressed |
| Methylprednisolone | Methylprednisolone | 40 | 25 |
| Omeprazole | Omeprazole | 39 | 12 |
| Finasteride | Finasteride | 38 | 11 |
| Memantine Hcl | Memantine Hcl | 38 | 11 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 38 | 11 |
| Prednisone | Prednisone | 37 | 21 |
| Glimepiride | Glimepiride | 36 | suppressed |
| Ramipril | Ramipril | 36 | 11 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 35 | 29 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 35 | 12 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 35 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 31 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 30 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 29 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 29 | 28 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 29 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 28 | 14 |
| Amiodarone Hcl | Amiodarone Hcl | 26 | suppressed |
| Olanzapine | Olanzapine | 26 | suppressed |
| Torsemide | Torsemide | 26 | suppressed |
| Atenolol | Atenolol | 24 | suppressed |
| Cephalexin | Cephalexin | 23 | 21 |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 23 | suppressed |
| Potassium Chloride | Potassium Chloride | 23 | suppressed |
| Clonazepam | Clonazepam | 22 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 22 | 17 |
| Sertraline Hcl | Sertraline Hcl | 22 | suppressed |
| Acyclovir | Acyclovir | 21 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 21 | 17 |
| Ezetimibe | Ezetimibe | 21 | suppressed |
| Amoxicillin | Amoxicillin | 20 | 17 |
| Buspirone Hcl | Buspirone Hcl | 20 | suppressed |
| Cilostazol | Cilostazol | 20 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 20 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 20 | suppressed |
| Telmisartan | Telmisartan | 20 | suppressed |
| Ursodiol | Ursodiol | 20 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 20 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 19 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 19 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 19 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 19 | 12 |
| Telmisartan-Hydrochlorothiazid | Telmisartan/Hydrochlorothiazid | 18 | suppressed |
| Fluconazole | Fluconazole | 17 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 17 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 17 | 17 |
| Synthroid | Levothyroxine Sodium | 17 | suppressed |
| Liothyronine Sodium | Liothyronine Sodium | 16 | suppressed |
| Valsartan | Valsartan | 16 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 16 | suppressed |
| Cefuroxime | Cefuroxime Axetil | 15 | suppressed |
| Celecoxib | Celecoxib | 15 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 15 | 15 |
| Dexamethasone | Dexamethasone | 14 | 13 |
| Estradiol | Estradiol | 14 | suppressed |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 14 | suppressed |
| Baclofen | Baclofen | 13 | suppressed |
| Clonidine | Clonidine | 13 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 13 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 13 | 11 |
| Breo Ellipta | Fluticasone/Vilanterol | 12 | suppressed |
| Humulin R | Insulin Regular, Human | 12 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 12 | suppressed |
| Neomycin-Polymyxin-Dexameth | Neomycin/Polymyxin B/Dexametha | 12 | 12 |
| Temazepam | Temazepam | 12 | suppressed |
| Terbinafine Hcl | Terbinafine Hcl | 12 | suppressed |
| Levemir | Insulin Detemir | 11 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 11 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 11 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 11 | suppressed |
Timeline
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $183.17 · 2 records | ABIOMED | — | — | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error